Drug intelligence / Profile preview

KY006

Development stage: Preclinical
Lead developer: KYDES Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

KY006 (also known as KY1106) is a synthetic anti-adherent therapeutic candidate under development by KYDES Pharmaceuticals. Administered intravenously, the agent is designed to inhibit pathological cellular and microbial adhesion to the vascular endothelium, a key driver in the pathogenesis of several acute and chronic conditions. Its primary applications include serving as an adjuvant therapy for drug-resistant malaria, managing sickle cell crisis by preventing vaso-occlusion, and treating leukemia-associated leukostasis. Additionally, KY006 is being investigated for its potential to prevent chemotherapy-induced micro-thrombosis and to treat drug-resistant bacterial infections, such as MRSA and VRE, by interfering with bacterial attachment and biofilm formation.

Other names: KY1106KY-1106KY 1106

Beyond the preview

Go deeper on KY006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KY006.

Explore the full profile